Drug Topics

JANUARY 11, 2024

A recent study found that reduced drug use was associated with a decrease in cravings, drug seeking behaviors, and depression severity.

191

191

Pharmacy Times

JANUARY 11, 2024

Variations and conditions included in existing state bills, however, limit the effectiveness of this approach.

153

153

Drug Topics

JANUARY 11, 2024

These findings can help health care professionals develop a family-centered treatment plan for pediatric type 1 diabetes, considered a “family disease” by study authors.

185

185

STAT

JANUARY 11, 2024

Since having a baby 10 months ago, I’ve learned many things. Chief among them: Pumping sucks. But skipping a session ends up being even more painful. Naturally, I expected navigating the J.P. Morgan Healthcare Conference in San Francisco would be more complicated this year. Somehow, between back-to-back meetings and presentations, I’d have to bust out that abominable contraption and do my thing.

145

145

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Pharmacy Times

JANUARY 11, 2024

These patients may have a similar genetic susceptibility for type 2 diabetes, although they have an individual risk for GDM independent of the risk of type 2 diabetes.

145

145

STAT

JANUARY 11, 2024

In the spring of 2020, Jamal Clay , a gifted young man who grew up in the south suburbs of Chicago, died by suicide. He was 19 years old. Jamal’s loved ones describe him as creative and talented, a leader in different youth-focused organizations in his community who supported and cared for those he loved. He was just as brilliant as he was kind.

145

145

STAT

JANUARY 11, 2024

Generative AI’s earliest applications in medicine have largely focused on curing not patients, but the plague of productivity physicians lose to digital documentation. Now, research suggests a way that large language models like ChatGPT could benefit both patients and providers: by automatically extracting a patient’s social needs from reams of text in their clinical records.

Documentation 144

Documentation 144

Pharmacy Times

JANUARY 11, 2024

The data also suggest that further studies investigating a plausible causal relationship between pneumonia and type 1 diabetes are needed.

139

139

STAT

JANUARY 11, 2024

A preliminary evaluation by the Food and Drug Administration did not find evidence that GLP-1 drugs like Ozempic and Wegovy cause suicidal thoughts or actions. The regulator has been reviewing reports of patients experiencing suicidal ideations while using this class of diabetes and obesity treatments, but because there was limited information provided and because other factors could be influencing the suicidal thoughts, the FDA determined that there was no clear link to the drugs, it said in a

FDA 139

FDA 139

Pharmacy Times

JANUARY 11, 2024

At a young age, hands-on learning about nutrition can promote long-term appreciation of fresh food and food experiences.

132

132

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

JANUARY 11, 2024

My daughter Katie was born with severe disabilities. She went on to develop profound autism, attention deficit disorder, and obsessive-compulsive disorder. The hardest part for her is knowing that she’s different but not understanding how or why. My career as a health care manager and now a researcher has been derailed and fragmented because I have a profoundly disabled daughter who has undergone so many treatments and required special schools.

Insurance 136

Insurance 136

PharmaVoice

JANUARY 11, 2024

As advanced therapies and patient perspectives strengthen their foothold in R&D, pharma is poised to deliver impactful treatments in record time.

131

131

STAT

JANUARY 11, 2024

SAN FRANCISCO — It seemed like there was a point during last year’s J.P. Morgan Healthcare Conference when we all collectively realized, “Oh, 2023 is going to be another slog.” Indeed, a downturn has weighed on the biotech industry for nearly three years. But this January, things feel different. Maybe it’s the abundance of sunlight that filled San Francisco this week.

135

135

Fierce Healthcare

JANUARY 11, 2024

SAN FRANCISCO — Virtual care company Hims & Hers is collaborating with Hartford HealthCare to connect patients in Connecticut with in-person primary and specialty care services. | Virtual care company Hims & Hers is collaborating with Hartford HealthCare to connect patients in Connecticut with in-person primary and specialty care services.

131

131

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Fierce Pharma

JANUARY 11, 2024

Dermavant’s topical cream Vtama, already on the market for plaque psoriasis as a steroid-free treatment, is compiling impressive data in pursuit of an FDA approval in atopic dermatitis (AD). | Dermavant’s topical cream Vtama, already on the market for plaque psoriasis as a steroid-free treatment, is compiling impressive data in pursuit of an FDA approval in atopic dermatitis (AD).

FDA 124

FDA 124

Pharmacy Times

JANUARY 11, 2024

High intensity interval training (HIIT) showed improved heart failure outcomes compared to medium chain triacylglycerol, used for endurance performance among athletes, and the usual care.

123

123

pharmaphorum

JANUARY 11, 2024

Generative AI is revolutionising the pharmaceutical industry, accelerating the speed to market for new drugs. Learn how regulatory processes, R&D, and clinical trials are being impacted by this innovative technology.

122

122

Fierce Healthcare

JANUARY 11, 2024

Generative AI models can identify social determinants of health (SDOH) in doctors’ notes, a new study finds. | The study showed that fine-tuned language models could identify the vast majority of patients with an adverse SDOH, which could augment efforts to identify patients who need social support.

121

121

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

pharmaphorum

JANUARY 11, 2024

The FDA is overseeing significant changes in R&D IT as it shifts towards advanced modalities and biologics. This includes the emergence of CRISPR-Cas9 gene editing technology and its potential impact on diseases like sickle cell anaemia. Learn more about these exciting developments in this article.

FDA 122

FDA 122

STAT

JANUARY 11, 2024

Rune Labs, maker of an Apple Watch app that can track symptoms related to Parkinson’s disease, announced Thursday $12 million in funding led by Nexus NeuroTech, a new venture capital fund focused on brain disorders. Rune in 2021 received Food and Drug Administration clearance for StrivePD, an Apple Watch app that uses the device’s sensors to track two Parkinson’s-related symptoms: tremors and dyskinesia, or the involuntary movements that are a side effect of medication.

120

120

Pharmacy Times

JANUARY 11, 2024

The update includes a recommended triple therapy with belimumab as a first line treatment for class III or IV lupus nephritis following the approvals of belimumab and voclosporin.

120

120

Fierce Healthcare

JANUARY 11, 2024

YouTube has launched a new feature to help users quickly find actionable and easy-to-follow videos for basic first aid and emergency care from authoritative health organizations. | Viewers searching for certain acute health topics can now access short explainer videos at the top of search results from reputable sources, developed in partnership with Mass General Brigham and the Mexican Red Cross.

120

120

Fierce Pharma

JANUARY 11, 2024

With sales declining for aging MS drug Fampyra, Biogen has exercised an option to return licensing rights outside of the U.S. to Acorda Therapeutics.

119

119

Fierce Healthcare

JANUARY 11, 2024

Charges for electronic, asynchronous clinician-patient messaging — or e-visits — have persisted in the wake of an early-2020 spike during the COVID-19 pandemic. | After an early 2020 spike, monthly claims for e-visits rose from 64,000 in June 2021 to 107,000 by Sept. 2022. The total number of health systems with at least 50 logged claims also rose about 40% from Q3 2021 to Q3 2022.

119

119

STAT

JANUARY 11, 2024

In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The Readout. To stay on top of the latest scoops and live reporting from the San Francisco conference,  join our newsletter list. JPM Week is finally drawing to a close, sending the drug industry’s many financiers scattering from San Francisco to their respective homes and ski destinations.

FDA 117

FDA 117

European Pharmaceutical Review

JANUARY 11, 2024

The European Commission (EC) has granted a marketing authorisation for Uzpruvo ® (AVT04) in Europe, a biosimilar candidate to Stelara ® (ustekinumab). Ustekinumab biologic Once the European Supplementary Protection Certificate (SPC) for Stelara expires in July 2024, this will open up market entry as soon as possible for Uzpruvo, now that it is approved in Europe” Ustekinumab is a human IgG1κ monoclonal antibody (mAb).

Immunization 115

Immunization 115

STAT

JANUARY 11, 2024

The Pashai family of Dallas on Thursday got some good news, but not exactly the news they had spent the last month praying for. The Texas Medicaid program, after denying coverage for an initial consult to begin experimental gene therapy that could save the life of their infant son, Sufyan, now says it will cover the costs for him to be assessed in person by doctors there.

115

115

pharmaphorum

JANUARY 11, 2024

In this new episode of the pharmaphorum podcast, host Nicole Raleigh speaks with James Burt, CEO of Pharmanovia, about the value-added medicines space.

115

115

STAT

JANUARY 11, 2024

Is biotech back from its downturn? Can Nvidia solve biology? And is it wise to do a deal on a party bus? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Recording from the J.P. Morgan Healthcare Conference, we discuss how a spate of deals and some intermittent sunshine seem to have brightened the outlook for biotech at the outset of 2024.

114

114

Drug Topics

JANUARY 11, 2024

According to Tyler Miliken, education about prior authorization, along with other insurance processes and policies, is critical for advancing patients down their path to care.

Insurance Processing 112

Insurance Processing Insurance 112

European Pharmaceutical Review

JANUARY 11, 2024

Quotient Sciences leverage more than 30 years of drug development expertise to support small molecule and synthetic peptide drug programmes, in both simple drug programmes as well as complex cases where specialised formulation expertise and technologies are required. All drug development programmes are challenging, with numerous stages that an active, lead molecule or new chemical entity (NCE) must transition through to gain regulatory approval and demonstrate its benefits to patients Find out m

111

111

pharmaphorum

JANUARY 11, 2024

CHMP has called in expert advisors to assist in the review of Eisai and Biogen’s Alzheimer's therapy Leqembi

111

111

STAT

JANUARY 11, 2024

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences.  Sign up to get it delivered in your inbox every Tuesday and Thursday. Teladoc makes its case for sustained growth Teladoc CEO Jason Gorevic used the JPM 2024 stage to explain why the company believes it’s got plenty of “running room” to grow its integrated care business that connects people to a host of virtual hea

108

108